GlassScriptPhysician profile
Jennifer Mace
NPI 1861632176
$2,082.29
in general payments reported to CMS, 2019-2025
23 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.80 · 2022: $248 · 2023: $574 · 2024: $651 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.55 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $208.99 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $200.47 | 2023-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.14 | 2022-2024 | Caplyta |
| Corium, LLC | $151.61 | 2023-2025 | Azstarys, Azstarys |
| Bausch Health US, LLC | $145.63 | 2022-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $142.10 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $131.89 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $120.64 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $113.81 | 2023-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $105.05 | 2023-2025 | Dyanavel Xr |
| Lundbeck LLC | $68.01 | 2023-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $53.22 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $45.53 | 2022-2025 | Fanapt |
| Almatica Pharma LLC | $42.18 | 2022-2023 | Loreev Xr, Sertraline Hcl, Venlafaxine |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $28.60 | 2023-2024 | Perseris |
| Janssen Scientific Affairs, LLC | $26.94 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.83 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2024 | |
| Supernus Pharmaceuticals, INC. | $16.67 | 2025 | Qelbree |
| Brainsway USA INC | $15.24 | 2023 | |
| Sage Therapeutics, LLC | $14.53 | 2025 | Zurzuvae |
| Avanir Pharmaceuticals, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.